Low Testosterone Lawsuits Reviewed in Wake of FDA Alert, Wright & Schulte LLC
Columbus, OH (PRWEB) February 13, 2014 -- Wright & Schulte LLC are concerned by the U.S. Food & Drug Administration’s (FDA) recent announcement that it was reviewing the safety of prescription medications used to treat men with low levels of testosterone. According to the FDA announcement, the review was prompted by the publication of two studies that suggested the use of testosterone drugs might increase the risk of heart attack, stroke and death in older men, or men with pre-existing heart disease. In addition to the FDA announcement Wright & Schulte has learned of 4 recent low testosterone lawsuits filed in the U.S. District Court, Northern District of Illinois that contend the men suffered serious heart problems due to the use of AndroGel, a drug used in the use of low testosterone therapy. (Case Nos: 1:14-cv-00776, 1:14-cv-00780, 1:14-cv-00777, and 1:14-cv-00772)
[fda.gov/Drugs/DrugSafety/ucm383904.htm, January 31, 2014]
In response, Wright & Schulte LLC has launched an investigation of AndroGel and other drugs, and is offering free testosterone lawsuit reviews to men who may have suffered serious cardiovascular events due to their use of the these medications, as well as their families.
According to the FDA, these medications are approved for the treatment of low testosterone levels that are caused by an underlying medical condition, such as problems with the hypothalamus gland or chemotherapy treatment side effects. None of the medications are approved to treat reduced testosterone levels related to the aging process.
According to an FDA alert issued on January 31, 2014, one of the two studies that prompted the agency’s safety review was published in the Journal of the American Medical Association, and found a 30% increased risk of stroke, heart attack and death in older men undergoing testosterone treatment who had pre-existing heart problems. The second, which was published in PLOS One, reported an increased risk of heart attack in older men, as well as in younger men with pre-existing heart disease, who underwent testosterone therapy.
Court documents filed in the U.S. District Court, Northern District of Illinois indicate that four testosterone treatment lawsuits were filed on February 4, 2014, on behalf of men who allegedly suffered serious heart problems due to the use of AndroGel. Among other things, the complaints raise questions about the marketing of prescription testosterone therapies, and accuse the manufacturers of the medications of promoting them as treatments for fatigue, low libido, and other problems associated with the aging process. The complaints further allege that these marketing tactics led to many patients being prescribed testosterone therapy, despite having normal levels of the hormone. (Case Nos: 1:14-cv-00776, 1:14-cv-00780, 1:14-cv-00777, and 1:14-cv-00772)
Testosterone treatment patients who suffered serious and life-threatening cardiovascular events while using one of these medications may be eligible to file their own testosterone therapy lawsuit. To learn more, or to arrange for a free legal consultation with an attorney at Wright & Schulte LLC, please visit yourlegalhelp.com.
About Wright & Schulte LLC
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free Lipitor lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.
Contact:
Wright & Schulte LLC
1-800-399-0795
http://www.yourlegalhelp.com
Richard Schulte, Wright & Schulte LLC, http://yourlegalhelp.com/, +1 1-800-399-0795, [email protected]
Share this article